#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7